The invention relates to an activity enhanced ketoreductase
mutant, which is derived from wild-type ketoreductase of Candida magnoliae, can transform 4-chloroacetoacetic acid
ethyl ester into (S)-4-chloro-3-hydroxy
butyric acid ethyl ester, and has one or more mutations of E9R, S42Q, T190L and E234M. The ketoreductase
mutant provided by the invention has obvious high
specific enzyme activity, which is increased by 2-20 times than wild-type ketoreductase. According to the invention, the
reaction conditions are mild, the requirement for equipment is low, the production process has need for high temperature or cooling, the
energy consumption is low, and as
enzyme catalysis has high efficiency and specific selectivity, production of the
statin drug key intermediate (S)-4-chloro-3-hydroxy
butyric acid ethyl ester by the method generates no by-product, and purification can be convenient. In addition, most solvents involved in the reaction of the invention are water, thus having low
discharge of three wastes, and being green and environment-friendly.